CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Regenerative Drugbased Cardiac Therapies

Myocardial infarction results from the interruption of blood supply to a part of the heart, causing heart cells to die. This is most due to coronary artery occlusion following the rupture of a vulnerable atherosclerotic plaque. The resulting ischemia and ensuing oxygen shortage, if left untreated for a sufficient period of time, can cause infarction of heart muscle tissue. Dr. Roman Schenk Recardio why regenerative medicine holds the promise of functional restoration by replenishing cardiomyocytes and blood vessels, and therefore also has the potential for complete tissue repair.
https://international-pharma.com/wp-content/uploads/2014/02/Regenerative.pdf

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026